Jennifer Nicholson
About Jennifer Nicholson
Jennifer Nicholson's Role at RAPT
Jennifer Nicholson joined RAPT in September 2022 as the Senior Vice President of Regulatory Affairs and Quality Assurance. She leverages over 20 years of expertise in the biotechnology and pharmaceutical industry to oversee regulatory practices and ensure quality compliance. Her role is crucial in guiding the regulatory strategy and maintaining high standards for product development and approval processes at RAPT.
Jennifer Nicholson's Regulatory Experience in Biotechnology and Pharmaceuticals
Jennifer Nicholson brings more than two decades of regulatory experience in the biotechnology and pharmaceutical sectors to her role. She has managed regulatory processes across all stages of development, with a focus on oncology, including both hematologic malignancies and solid tumors. Her background equips her to navigate complex regulatory frameworks and contribute to successful product approvals.
Jennifer Nicholson's Education and Qualifications
Jennifer Nicholson holds a B.S. in Biochemistry and Cell Biology from the University of California, San Diego. Additionally, she earned an M.H.A. from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. These academic credentials provide a strong foundation for her extensive career in regulatory affairs and quality assurance within the biotechnology and pharmaceutical industries.
Jennifer Nicholson's Previous Roles
Before joining RAPT, Jennifer Nicholson served in various high-profile regulatory roles. Most recently, she was the Vice President of Regulatory Affairs at Kronos Bio. She has also been the Head of Global Regulatory Science at Acerta Pharma, part of the AstraZeneca Group, where she led the global regulatory team for the Calquence (acalabrutinib) US NDA, securing accelerated approval in 2017. Additionally, she worked as Senior Director of Regulatory Affairs at Bavarian Nordic, focusing on immuno-oncology and vaccine products. Her career also includes roles at Jazz Pharmaceuticals, Onyx Pharmaceuticals, and Genentech, where she worked on multiple hematology and oncology products.